Core A: Administration The Administrative Core A (Admin Core) provides the administrative framework to support the four Projects and the other Core of this PPG. Its main focus is to allow the PPG investigators to dedicate their efforts on scientific advances to fulfill the goals of this PPG. The Core is led by Antoni Ribas, M.D. with the Core Co- lnvestigator David Gjertson, Ph.D., the senior PPG biostatistician. With this resubmission Core A incorporates a new service, bioinformatics support, which is a common need for the four Projects to allow adequate interpretation of high throughput data and the ability to use advanced algorithms for its analysis This will be provided by Stan Nelson, M.D. and Tom Graeber, Ph.D. It is supported by a staff biostatistician, a regulatory coordinator, an administrative and a fund manager, and a clinical trials coordinator and data manager. The Core has two specific Aims.
Aim 1 is focused on fostering the scientific aspects of the PPG providing oversight of meeting the milestones and objectives for each Project and Core. This will be facilitated by a series of in-process and formal evaluation meetings with the oversight of the Internal Advisory Board (lAB) made up by four senior Investigators at UCLA and Caltech, James Economou, M.D., Ph.D., James Heath, Ph.D. (Caltech), Owen Witte, M.D., and Hong Wu, Ph.D. This oversight and scientific support is extended by the engagement of three External Expert Consultants (EEC). Boris Bastian, M.D., Ph.D. (UCSF), Charles Sawyers, M.D. (MSKCC) and Cassian Yee (Fred Hutch).
Aim 2 is focused on providing the appropriate administrative and fiscal support for the daily activities within PPG. This includes administrative and coordination support, facilitating data and resource sharing plans, clinical trial and biospecimen regulatory, study coordination and data management.

Public Health Relevance

The Admin Core will support all Projects and Cores to allow them to focus the efforts on the proposed scientific plans. As such, it is an integral part of the PPG scientific goals and provides Its relevance for the proposed patient-oriented research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA168585-02
Application #
8686788
Study Section
Special Emphasis Panel (ZCA1-RPRB-C)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$245,187
Indirect Cost
$85,665
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Nowicki, Theodore S; Berent-Maoz, Beata; Cheung-Lau, Gardenia C et al. (2018) A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab. Clin Cancer Res :
Mehta, Arnav; Kim, Yeon Joo; Robert, Lidia et al. (2018) Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. Cancer Discov 8:935-943
Cheng, Larry C; Li, Zhen; Graeber, Thomas G et al. (2018) Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer. J Vis Exp :
Jan, Yu Jen; Chen, Jie-Fu; Zhu, Yazhen et al. (2018) NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Adv Drug Deliv Rev 125:78-93
Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355
Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95
Hong, Aayoung; Moriceau, Gatien; Sun, Lu et al. (2018) Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov 8:74-93
Nowicki, Theodore S; Hu-Lieskovan, Siwen; Ribas, Antoni (2018) Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J 24:47-53
Puig-Saus, Cristina; Parisi, Giulia; Garcia-Diaz, Angel et al. (2018) IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System. Clin Cancer Res :
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:

Showing the most recent 10 out of 72 publications